[ Back to EurekAlert! ] Public release date: 22-Sep-2004
[ | E-mail | Share Share ]

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
44-015-367-72181
European Organisation for Research and Treatment of Cancer

16th EORTC – NCI – AACR Symposium – 'Molecular Targets and Cancer Therapeutics'

The 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics brings 2,000 international cancer experts together to present new data on leading-edge basic, translational and early clinical research.

News briefing:
12.30 hrs CET Thursday 30 September

Speakers and topics:
* Dr. Jacqueline Limpens: Study shows lycopene and vitamin E inhibits growth of prostate tumours in mice, underpinning epidemiological evidence. Phase II trial in patients now under way.

* Dr. Olivier Feron: A revolutionary approach to angiogenesis - exploiting tumour blood vessels to boost chemotherapy and radiotherapy instead of (or before) killing them. Successful mouse study leads to patient trial.

* Professor Eric Van Cutsem: International trial results shows way to measure success of centuximab (Erbitux). Randomised study now under way

Chairman: Professor Jaap Verweij (EORTC chairman of conference scientific committee) together with scientific committee co-chairmen Dr Janet Dancey (NCI) and Dr Eric K Rowinsky (AACR).

NB: any reports involving the topics outlined above are embargoed until the time and date of the news briefing.

Journalists wishing to dial in to the news briefing should contact Margaret Willson by Friday 25 September

More information:
Margaret Willson
Conference Press Officer
Tel: 44-0-1536-772181
44-0-7973-853347

Conference media centre:
From 16.00 hrs CET Monday 27 September to 17.00 hrs CET Friday 1 October
Tel: 41-22-761-22-05
Fax: 41-22-761-22-11

###


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.